|

Sacituzumab tirumotecan Clinical Trials

22 actively recruiting trials across 14 locations

▼ -3 trials since May 2026

Also known as: MK-2870, SKB264, SKB264, MK-2870, Sac-TMT, furmonertinib +1 more

Pipeline

Phase 2: 5Phase 3: 11Phase 1/2: 6

Top Sponsors

  • Merck Sharp & Dohme LLC18
  • Tianjin Medical University Second Hospital1
  • Tianjin Medical University Cancer Institute and Hospital1
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1
  • Fujian Cancer Hospital1

Indications

Other4 trials

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Phase 2
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Phase 2
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
Phase 2
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
Phase 2

Mobile, Alabama3 trials

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

USA Mitchell Cancer Institute ( Site 0090)

Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

University of South Alabama, Mitchell Cancer Institute ( Site 6033)

Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Infirmary Cancer Care ( Site 0001)

Phase 3

Tucson, Arizona2 trials

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)

Phase 1/2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927)

Phase 1/2

Miami Beach, Florida2 trials

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Mount Sinai Comprehensive Cancer Center ( Site 6000)

Phase 3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Mount Sinai Cancer Center ( Site 0029)

Phase 3

Birmingham, Alabama1 trial

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

University of Alabama at Birmingham ( Site 0006)

Phase 3

Daphne, Alabama1 trial

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Southern Cancer Center (SCC) ( Site 8004)

Phase 2

Chandler, Arizona1 trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Ironwood Cancer & Research Centers ( Site 0066)

Phase 3

Gilbert, Arizona1 trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Banner MD Anderson Cancer Center ( Site 0066)

Phase 3

Phoenix, Arizona1 trial

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Mayo Clinic in Arizona - Phoenix ( Site 0147)

Phase 3

Little Rock, Arkansas1 trial

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060)

Phase 3

Bakersfield, California1 trial

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Michael G Oefelein Clinical Trials ( Site 0053)

Phase 1/2

Los Angeles, California1 trial

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

UCLA ( Site 0317)

Phase 1/2

Clermont, Florida1 trial

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Clermont Oncology Center ( Site 0041)

Phase 1/2

Traverse City, Michigan1 trial

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Munson Medical Center ( Site 0812)

Phase 3

Pittsburgh, Pennsylvania1 trial

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

UPMC Hillman Cancer Center ( Site 1904)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.